Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study
Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Herbert I. Hurwitz(Duke Medical Center), Kanwal Raghav(The University of Texas MD Anderson Cancer Center), Robert R. McWilliams(Mayo Clinic in Arizona), Marwan Fakih(City Of Hope National Medical Center), Ari M. Vanderwalde(West Cancer Center), Charles Swanton(The Francis Crick Institute), Razelle Kurzrock(University of California, San Diego), Howard A. Burris(Tennessee Oncology), Christopher J. Sweeney(Dana-Farber Cancer Institute), Ron Bose(Washington University in St. Louis), David R. Spigel(Tennessee Oncology), Mary Beattie, Steven Blotner, Alyssa Stone, Katja Schulze, Vaikunth Cuchelkar, John D. Hainsworth(Sarah Cannon)
Cited by 564
Abstract
Related Papers
No related papers found
Powered by citation graph analysis